FDA requests public comments on ibogaine trial design
FDA is opening a docket to receive comments on design elements for early-phase trials of ibogaine drug products, with a deadline of November 20, 2026. The request follows guidance issued July 14, 2026 and seeks input on dose selection, safety monitoring, eligibility criteria and other protocol elements.
Primary source
Federal Register notice, October 6, 2026
Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information
Read the source: Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information federalregister.gov
Machine-summarized from the source above; not independently reported. How we use automation